Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Similar documents
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Assist Devices in STEMI- Intra-aortic Balloon Pump

DECLARATION OF CONFLICT OF INTEREST

Circulatory Support: From IABP to LVAD

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Rhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale

Bridging With Percutaneous Devices: Tandem Heart and Impella

Introduction to Acute Mechanical Circulatory Support

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Percutaneous Mechanical Circulatory Support Devices

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

Management of Cardiogenic shock. Prof. Christian JM Vrints

Update on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada

Ventricular Assisting Devices in the Cathlab. Unrestricted

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.

Recovering Hearts. Saving Lives.

Ted Feldman, M.D., MSCAI FACC FESC

AllinaHealthSystem 1

Management of Acute Shock and Right Ventricular Failure

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017

Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

The majority of patients with cardiomyopathy

Extra Corporeal Life Support for Acute Heart failure

Mechanics of Cath Lab Support Devices

Mechanics of Cath Lab Support Devices

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ

Emergency surgery in acute coronary syndrome

Andrew Civitello MD, FACC

Percutaneous Cardiopulmonary Support after Acute Myocardial Infarction at the Left Main Trunk

Cardiogenic Shock and Initiatives to Reduce Mortality

IABP SHOCK II trial:

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

Case - Advanced HF and Shock (INTERMACS 1)

MANAGEMENT OF CARDIOGENIC SHOCK

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Cardiogenic Shock. Carlos Cafri,, MD

เอกราช อร ยะช ยพาณ ชย

A Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany

DECLARATION OF CONFLICT OF INTEREST

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support

Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!

Section 6 Intra Aortic Balloon Pump

Acute Mechanical Circulatory Support Right Ventricular Support Devices

Conflict of Interest Slide

Hemodynamic Monitoring and Circulatory Assist Devices

PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR

The development of cardiogenic shock portends an extremely poor prognosis. Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction

Acute Myocardial Infarction Complicated by Cardiogenic Shock

The Counter HF Clinical Study for Heart Failure

Cardiogenic Shock in Acute MI

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

The World s Smallest Heart Pump

Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Guideline compliance, utilization trends

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4

CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)

Understanding the Pediatric Ventricular Assist Device

Device Therapy for Heart Failure

Accepted Manuscript. Improving Survival in Cardiogenic shock: Is Impella the Answer?,, James J Glazier MD, Amir Kaki MD S (18)

Right Ventricular Failure: Prediction, Prevention and Treatment

External Counterpulsation

University of Leipzig Heart Center

Principles of intra-aortic balloon pump counterpulsation

HOW TO PERFORM LEFT VENTRICULAR ASSISTANCE IN THE CATHLAB. Andreas Baumbach, MD FESC FRCP Bristol Heart Institute University Hospitals Bristol UK

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

Experience with Intraaortic Balloon Counterpulsation

Surgical Options for Temporary MCS

Ischemic Mitral Valve Disease: Repair, Replace or Ignore?

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities

Intra-aortic balloon counterpulsation in US and non-us centres: results of the Benchmark Registry. COHEN, Marc, et al. Abstract

LM stenting - Cypher

Final published version:

Epidemiology of Heart Failure in Adults

Acute heart failure: ECMO Cardiology & Vascular Medicine 2012

Ischemic Ventricular Septal Rupture

The use of Intra Aortic Baloon Pump in Patients undergoing Coronary Artery Bypass Grafting at the Aga Khan University Hospital, Karachi

MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

High Risk PCI for Heart Failure

MEDICAL POLICY Ventricular Assist Devices

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment

Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials

VENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Echo assessment of patients with an ECMO device

Implantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013

Who is the high risk patient?

From Recovery to Transplant: One Patient's Journey

Transcription:

John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87 1961 Extracorporeal blood pump (arterial counterpulsation) 1962 Diastolic balloon pumping in the aorta (IABP) 1968 The first 2 clinical applications of the IABP 1980 Percutaneous IABP insertion Today Worldwide >200,000 IABPs annually Harken DV, JTCS 1961;41:447-58 Moulopoulos SD, AHJ 1962;63:669-75 Kantrowitz, JAMA 1968;203:135-140 Bregman D, AJC 1980;46:261-64

IABP Inflation IABP Deflation

Normal Heart Counterpulsation IABP on LV Mechanoenergetics IABP OFF 14% LV Stroke Work IABP ON 17% LV End-Systolic Pressure 10% LV End-Diastolic Pressure 14% LV Stroke Work 10% Coronary Blood Flow Diastolic AOP Bonios et al, Int J Cardiol, 2008

Failing Heart Counterpulsation IABP on LV Mechanoenergetics IABP OFF IABP ON Bonios et al, Int J Cardiol, 2008 7% LV End-Systolic Pressure 18% LV End-Diastolic Pressure 7% LV Stroke Work 11% Coronary Blood Flow Diastolic AOP

IABP Complications (1982-2000): Major limb ischemia 16 14 12 10 % 8 6 4 2 0 1982 1986 1987 1989 1990 1993 1995 1996 1997 2000

IABP: Indications in Benchmark Registry (n=16909) Post-MI cardiogenic shock (CS or CS with mechanical complications*) : 25% Weaning from CPB : 16% Hemod. support for high risk cath and PCI : 21% Preoperatively in high-risk CABG : 13% UA refractory to medical therapy : 12% CPB=Cardiopulmonary bypass UA=Unstable angina, * MR, PMR, VSR Am J Cardiol 2006;97:1391-8

Post discharge long term survival of patients with AMI with and without CS Am J Cardiol 1999;84:18

IABP + Thrombolysis in Post-MI CS Ohman E, Nanas J et al, J Thrombosis Thrombolysis 2005;19:33-39 Kovack PJ et al, J Am Coll Cardiol 1997;29:1454-1458 Andreson RD et al, J Am Coll Cardiol 1997;30:708-715 Barron HV et al, Am Heart J 2001;141:933-939

Survival of patients with post-mi CS and delayed (1-10d) revascularization 6-month survival Nanas et al. Coronary Artery Disease 2008;19:521-6

IABP utilization in patients with post-mi CS 97 01 09 00 99 Eur Heart J 2010;31:1828

New PVAD(TandemHeart, Impella Recover LP2.5) vs IABP in post-mi CS randomized studies (meta-analysis) New PVAD -Impella Recover LP 2.5 -TandemHeart -Reitan catheter pump n (IABP)=47 n (LVAD)=53 IABP is the device of first choice for the post-mi CS Eur Heart J 2010; 31:1828

Potential new indications for the IABP 1. Adjunctive treatment for patients with extensive AMI without CS 2. Bridge to decision making 3. Bridge to transplantation

IABP adjunctive to PPTCA for patients with extensive AMI without CS IABP followed by reperfusion in AMI: a. experimental study (dogs) b. experimental study (pigs) Group 1 (NR) Group 2 (R) Group 3 (R+IABP) Nanas J et al, Ann Thorac Surg 1996;61:629 Pierrakos et al. Submitted for publication

IABP application before vs after PPTCA in patients with post MI CS Mohamed Abdel-Wahab et al, Am J Cardiol 2010;105:967

After PPTCA adjunctive IABP application in patients with extensive AMI without CS 30 days mortality Cardiol Clin 2010;28;169 A new randomized study is needed

IABP as a bridge to decision making No of patients Mean (range) days Survival Kantrowitz et al 27 33 (20-71) 70.4% Simonsen et al 24 28 (10-66) 95.8% Nanas J et al 10 56 (10-180) 90% Overall 61 35 (10-180) 84% Kantrowitz et al, Am J Cardiol 1988, Simonsen et al, Eur J Heart Failure 2009, Nanas et al, unpublished data The IABP seems a suitable device for more than a short period of MA

IABP as a bridge to transplantation 40/179 listed for Tx, needed mechanical assistance (2001-2007) Patients (n) Survival to Tx Mean duration in days (range) No need for MA 139 100% (139/139) NR IABP only 33 97% (32/33) 21 (3-66) VAD/ ECMO 7 86% (6/7) 25 (1-49) Simonsen et al, Eur J Heart Failure 2009;11:709-714 MA = Mechanical assistance

New counterpulsation device suitable for long term mechanical assistance CPD (SV=30-40 ml) Implanted on the subclavian artery Experimental studies only ASAIO J 2008;54:578-584

Sunshine Heart C-Pulse device Implanted around the ascending aorta Implanted in 1 patient Duration of support 7 months Ann Thor Surg 2008;85:2122

New counterpulsation device suitable for long term mechanical assistance Kantrowitz CardioVAD Device Implanted on the descending aorta Implanted in 5 patients 1 died perioperatively 3 survived up to 30 days 1 survived 7 months Circulation 2002;106:I-183-I-188

New counterpulsation device suitable for long term mechanical assistance KardiaPulse Device 60 ml maximum stroke volume Implanted in 4 patients with severely deteriorating HF resulting in infractable CS. Support up to 54 days Nanas et al, JACC 1996; 7: 1028-35

Summary (1/2) 1. All patients with post MI CS without contraindication must undergo IABP assistance in conjunction with reperfusion even if delayed 2. The IABP seems to be a suitable device for more than a short period of support as a bridge to decision making or as a bridge to cardiac transplantation

Summary (2/2) 3. Experimental data support the use of the IABP before PPTCA in patients with a large AMI without CS. A randomized clinical study is needed. 4. The emerging new counterpulsation devices suitable for long term mechanical assistance are highly promising and their use might expand the indications to less severe HF for long term mechanical assistance.

Backup

Suga-Sagawa law Hypothetical P-V curves without (1) and with (2) IABP assistance Nanas J et al, Cardiology 1994;84:156

Hemodynamic variables affected by the IABP Left-ventricular pressures Left-ventricular work Diastolic aortic pressure Ejection fraction Cardiac output Coronary blood flow Nanas JN et al, Cardiology 1994;84:156-167

Reperfusion therapy and mortality in patients with Post MI CS assisted by the IABP Variable 1990-1994 (n=69) 1995-1999 (n=99) 2000-2004 (n=132) p value Reperfusion therapy 66% 77% 89% < 0.001 30-day Mortality 52% 41% 36% < 0.05 Am J Cardiol 2009; 104:327

Summary (1/2) The purposes of the diastolic pumping devices are: to increase the blood flow during diastole, especially through the coronary arteries to decrease the end-diastolic pressure, and therefore to decrease the work of the failing left ventricle The entire inflation had to be completed at least 20 msec before the next ventricular systole began, in order to assure lowering of the end-diastolic pressure in the aorta Moulopoulos SD et al, Am Heart J 1962;63:669

Summary (2/2) The diastolic arterial support to the circulation as described would probably be contraindicated in cases of aortic insufficiency Moulopoulos SD et al, Am Heart J 1962;63:669-75

Use of IABC in CS complicating acute myocardial infarction. Do we really need more evidence? We conclude that the benefit / risk ratio of intraaortic counterpulsation in AMI patients with preshock or CS is likely to be high, and the routine use of this device should be highly recommended in these patients as current guidelines state. In addition, the APACHE II score may be clinically useful as a simple bedside prognostic indicator in this patient group Cardiol Clinic 2010;28:169

Moulopoulos SD et al, Am Heart J 1962;63:669-75

Time course of the effect of the IABP on CBF during reperfusion: experimental study Submitted for publication

Time on Cardiopulmonary Bypass (min.) Pre-operative IABP Support in High-Risk* Coronary Patients 120 (p < 0.001) 100 80 60 40 20 88 105 0 IABP Group Control Group (no IABP) * EF, LM, Redo, UA Eur J Cardiothorac Surg 1997; 11:1097

The effect of IABP on CBF during reperfusion in AMI: experimental study Normal Heart 60 ο min of reperfusion 120 ο min of reperfusion Submitted for publication

Brief history 78-year-old man with a history of MI and substernal chest pain accompanied by faintness starting 2 hrs before admission On admission, BP=70/50mmHg with weak regular pulses 100/min The ECG revealed alternate L and RBBB

Coronary angiography

After Primary PCI

Clinical course Before Primary PCA: Blood Pressure 70/50 mmhg After Primary PCA: Blood Pressure 110/60 mmhg

Percutaneous left ventricular support devices The use of IABP is a representative example of a treatment based on a concept that becomes clinical practice. The IABP has evolved into an amateur technology 4 decades after its introduction. Owing to the ease of percutaneous implantation, the low cost, and the beneficial hemodynamics at a low complication rate, it continues to be the most common mechanical cardiac assistance method in the catheterization laboratory Cardiol Clinic 2010;28:169

Eur Heart J 2009;30:2102 Thiele et al, Eur Heart J 2005;26:1276-1283 Burkoff et al, Am Heart J 2006;152:469e461-468 Seyfarth et al, J Am Coll Cardiol 2008;52:1584-1588

Eur Heart J 2009;30:2102

Am J Cardiol 2009; 104:327

Optimal Timing of Preoperative IABP Support in High-Risk Coronary Patients The time period (2h, 12h, 24h) of preoperative IABP assistance did not show any differences in the time on Cardiopulmonary Bypass or the clinical outcome Annals Thorac Surg 1999; 68:934-939

IABP adjunctive to PPTCA for patients with extended AMI without CS Reperfusion plus IABP in AMI: experimental study (pigs) Submitted for publication

IABP as a bridge to transplantation Post mortality in pre transplantation ambulatory (stable), needed IABP or LVAD / ECMO assistance No of patients 30 days 1 year Stable pts to Tx 135 3.7% 11.1% IABP assisted to Tx 32 6.2% 9.4% VAD/ECMO assisted to Tx 7 17% 33% Simonsen et al, Eur J Heart Failure 2009;11:709-714

IABP as a bridge to recovery Recovery of the peripheral organs 10 patients Duration of support 56±48 days Range 10-180 days Nanas J et al, unpublished data